Key result
First oral PCSK9 inhibitor gains FDA approval to lower LDL-C as an alternative to injectables.
Answers are grounded in this paper and cite their sources.
The FDA approval of the first oral PCSK9 inhibitor offers a new, non-injectable therapeutic option for LDL cholesterol reduction.
The US Food and Drug Administration (FDA) approved the first oral protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to reduce low-density lipoprotein (LDL) cholesterol. PCSK9 inhibitors have previously been available only as injectable therapies.
No takes yet. Share an insight, caveat, or question.
Samantha Anderer (2026) studied this question. The first oral PCSK9 inhibitor was approved by the FDA to reduce low-density lipoprotein cholesterol, providing a new alternative to existing injectable therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: